INCS provides better nasal symptom control and quality of life outcomes compared to OAH 1
The same results were first published in Juel-Berg N, et al. Am J Rhinol Allergy 2017;31(1):19–28. The figure has been independently created by GSK from the original data.
A meta-analysis showed INCS provides better nasal symptom control and QoL outcomes compared to OAH. 1
AR: allergic rhinitis; INCS: intranasal corticosteroid; OAH: oral antihistamine.
Avamys is a registered trademark of the GlaxoSmithKline group of companies